Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YF476 in Barrett's esophagus
2014-002418-22Phase 2Completed
- Sponsor
- Trio Medicines Ltd
- Start
- Apr 2015
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial in Barrett's esophagus comparing Netazepide with Placebo (2 arms). Primary endpoint: Ki67 expression in Barrett's esophagus biopsies. Started Apr 2015; status: completed.
02
Drugs
netazepide
03
Conditions
Barrett's esophagus
Beyond the preview
Go deeper on 2014-002418-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002418-22.